Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?

ROS1-rearranged (also known as ROS1 fusion-positive) non-small-cell lung cancer is an uncommon but distinct molecular subgroup seen in approximately 1–2% of cases. Oncogene addiction due to constitutive ROS1 tyrosine kinase activation has allowed development of molecularly targeted therapies with re...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehgal, Kartik, Piper-Vallillo, Andrew J., Viray, Hollis, Khan, Adeel M., Rangachari, Deepa, Costa, Daniel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410006/
https://www.ncbi.nlm.nih.gov/pubmed/32776005
http://dx.doi.org/10.21037/pcm-2020-potb-02

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410006/
https://www.ncbi.nlm.nih.gov/pubmed/32776005
http://dx.doi.org/10.21037/pcm-2020-potb-02

Ejemplares similares